Your session is about to expire
← Back to Search
Tucatinib in Combination with Palbociclib and Letrozole for Breast Cancer
Study Summary
This trial is testing a new combination drug treatment for metastatic hormone receptor positive and HER2-positive breast cancer.
- Breast Cancer
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2023 Phase 1 & 2 trial • 42 Patients • NCT03054363Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have trouble swallowing pills or have a serious stomach problem that could prevent medicine from being absorbed properly when taken by mouth.You have had a bad allergic reaction to aromatase-inhibitor drugs in the past.You have previously been treated with certain medications that target specific proteins in the body.You are currently taking a medication that is still being tested and not yet approved for use.You experienced side effects from previous cancer treatments that have not fully improved, except for mild nerve damage and hair loss.You have already been treated with medications like palbociclib, abemaciclib, ribociclib, or other similar drugs being tested in clinical trials.You have a condition affecting the central nervous system (brain and spinal cord) that meets the specific requirements for this study.
- Group 1: Phase 1b
- Group 2: Phase II
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are adults aged 20 and above eligible for this experiment?
"According to the qualifications laid out for this trial, participants must be aged 18 or over and no older than 100."
Are there several locations conducting this research endeavor within the city?
"The clinical trial is operating in 6 different places, including the University of Arizona at Tucson, University of Texas Health Science Center San Antonio and Stony Brook University. Several other locations are also involved with this project."
Could you provide a summary of any previous research for the combination of Tucatinib, Palbociclib and Letrozole?
"Presently, there are 272 active clinical trials investigating the efficacy of Tucatinib in combination with Palbociclib and Letrozole. Out of these, 52 have reached phase 3 with most occurring in Melbourne, Victoria. Across 16858 locations around the world studies involving this drug cocktail are taking place."
Are there vacancies for prospective participants in this research project?
"At this time, recruitment for the clinical trial has been filled and is no longer accepting new participants. This medical study was first posted on November 27th 2017 and underwent its most recent update on March 8th 2022. However, there are currently 2,600 trials seeking patients with breast cancer as well as 272 studies involving Tucatinib in conjunction with Palbociclib and Letrozole that remain open to enrolment."
How many participants have registered for this investigation?
"This study is no longer enlisting patients, as the trial was first posted on November 27th 2017 and last updated on March 8th 2022. Alternatively, if you are looking for other clinical trials related to breast cancer there are currently 2600 available with 272 of those specifically recruiting participants for Tucatinib in combination with Palbociclib and Letrozole."
Is it feasible for me to join this clinical experiment?
"This clinical trial is open to participants who are between 18 and 100 years old, have breast cancer, and meet other criteria. The research team seeks 42 individuals for their study."
What medical condition is the drug combination of Tucatinib, Palbociclib and Letrozole typically prescribed for?
"Tucatinib in Combination with Palbociclib and Letrozole is a recommended treatment for tamoxifen, postmenopause, advanced directives and carcinoma."
Share this study with friends
Copy Link
Messenger